Merck & Co. is at a critical transition. Analysts are increasingly confident in its ability to grow beyond blockbuster Keytruda.
The strategy is diversification. Recent acquisitions, including Cidara, bring over $20 billion in peak sales potential.
Sotatercept could be transformative for pulmonary hypertension. The CADENCE study showed positive results.
Keytruda patent extended to November 2029. The company plans to convert patients to Qlex.
Fiscal 2025 revenue projected at ~$64.8B. Fiscal 2026 estimates range from $68.0B to $68.7B.
CD388 could be a best-in-class influenza antiviral with peak sales up to $8.4B.
HIV combos and renal cancer programs enhance diversification.
Stock trades at about 8.7x projected 2026 earnings, a discount to the S&P 500.
Dividend paid for 56 consecutive years. Gross profit margin 76.73%, ROE 19%.
Stock returned 49.46% in the past year, 19% in six months. It is 10% below its 52-week high.
Key risk: Keytruda patent loss. Regulatory pricing pressures could impact.
Company offers multiple catalysts. Many clinical readouts expected through 2027.
